SG11201407600UA - Novel process for preparation of antibody conjugates and novel antibody conjugates - Google Patents

Novel process for preparation of antibody conjugates and novel antibody conjugates

Info

Publication number
SG11201407600UA
SG11201407600UA SG11201407600UA SG11201407600UA SG11201407600UA SG 11201407600U A SG11201407600U A SG 11201407600UA SG 11201407600U A SG11201407600U A SG 11201407600UA SG 11201407600U A SG11201407600U A SG 11201407600UA SG 11201407600U A SG11201407600U A SG 11201407600UA
Authority
SG
Singapore
Prior art keywords
london
international
polytherics
bioscience
limited
Prior art date
Application number
SG11201407600UA
Inventor
John Burt
Antony Godwin
George Badescu
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1210838.7A external-priority patent/GB201210838D0/en
Priority claimed from GB201306706A external-priority patent/GB201306706D0/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of SG11201407600UA publication Critical patent/SG11201407600UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 December 2013 (27.12.2013) WIPOIPCT (10) International Publication Number WO 2013/190292 A3 (51) International Patent Classification: A61K 47/48 (2006.01) C07K16/32 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/GB2013/051593 (22) International Filing Date: 19 June 2013 (19.06.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1210838.7 19 June 2012 (19.06.2012) GB 1306706.1 12 April 2013 (12.04.2013) GB (71) Applicant: POLYTHERICS LIMITED [GB/GB]; The London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH (GB). (72) Inventors: BURT, John; Polytherics Limited, The London Bioscience Innovation Centre, 2 Royal College Street, __ London NW1 0NH (GB). GODWIN, Antony; Polytherics Limited, The London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH (GB). BADES- CU, George; Polytherics Limited, The London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH (GB). __ (74) Agents: SCOTT, Susan Margaret et al.; Abel and Imray, 20 Red Lion Street, London WC1R 4PQ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date publication of of the international search report: 20 March 2014 CJ o\ CJ o 0\ i-H o CJ (54) Title: NOVEL PROCESS FOR PREPARATION OF ANTIBODY CONJUGATES AND NOVEL ANTIBODY CONJUG- O ATES (57) Abstract: The present invention concerns process a for the preparation of an antibody conjugate comprising the step of reacting an engineered antibody having single inter-heavy chain a disulfide bond with conjugating a reagent that forms bridge between a the two cysteine residues derived from the disulfide bond.
SG11201407600UA 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates SG11201407600UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1210838.7A GB201210838D0 (en) 2012-06-19 2012-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates
GB201306706A GB201306706D0 (en) 2013-04-12 2013-04-12 Novel process for preparation of antibody conjugates and novel antibody conjugates
PCT/GB2013/051593 WO2013190292A2 (en) 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates

Publications (1)

Publication Number Publication Date
SG11201407600UA true SG11201407600UA (en) 2014-12-30

Family

ID=48699187

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407600UA SG11201407600UA (en) 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates

Country Status (16)

Country Link
US (1) US20150125473A1 (en)
EP (1) EP2861261A2 (en)
JP (1) JP2015521615A (en)
KR (1) KR20150023027A (en)
CN (1) CN104379178A (en)
AU (1) AU2013279099A1 (en)
BR (1) BR112014031613A2 (en)
CA (1) CA2876365A1 (en)
HK (1) HK1204924A1 (en)
IL (1) IL235646A0 (en)
IN (1) IN2014DN10428A (en)
MX (1) MX2014015682A (en)
RU (1) RU2015101333A (en)
SG (1) SG11201407600UA (en)
WO (1) WO2013190292A2 (en)
ZA (1) ZA201408916B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015008376A2 (en) * 2012-10-24 2017-09-26 Polytherics Ltd drug-protein conjugates
NO2789793T3 (en) * 2012-10-24 2018-01-27
EA038512B1 (en) 2013-03-15 2021-09-08 Регенерон Фармасьютикалз, Инк. Maytansinoid conjugates and therapeutic use thereof
MX2016002149A (en) 2013-08-26 2016-10-28 Regeneron Pharma Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses.
WO2015179734A1 (en) * 2014-05-23 2015-11-26 Novartis Ag Methods for making conjugates from disulfide-containing proteins
EP3148592A2 (en) * 2014-06-02 2017-04-05 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
SG11201700365TA (en) 2014-07-24 2017-02-27 Genentech Inc Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
JP2017534612A (en) 2014-10-14 2017-11-24 ポリセリックス・リミテッド Method for conjugation of peptides or proteins using a reagent comprising a leaving group including a PEG moiety
EP3220956B1 (en) * 2014-10-24 2023-08-09 Abzena (UK) Limited Conjugates and conjugating reagents
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
AU2015360724A1 (en) * 2014-12-08 2017-07-13 Sorrento Therapeutics, Inc. c-Met antibody drug conjugate
ES2747386T3 (en) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Heteroarylene-linked benzodiazepine dimers, conjugates thereof and methods of preparation and use
EP3262068A1 (en) * 2015-02-05 2018-01-03 Ablynx N.V. Nanobody dimers linked via c-terminally engineered cysteins
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
EP3165237B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
EP3442595A1 (en) * 2016-04-14 2019-02-20 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
TWI763732B (en) * 2016-11-07 2022-05-11 美商西雅圖遺傳學公司 Distribution of engineered-cysteine caps
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
JP7232925B2 (en) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド Process for preparing antibody drug conjugates with improved homogeneity
EP4110383A4 (en) * 2020-02-26 2024-02-28 University of Maryland, College Park Compositions and methods for mucosal vaccination against sars-cov-2
WO2021115497A2 (en) * 2020-12-08 2021-06-17 和铂医药(上海)有限责任公司 Protein-drug conjugate and site-specific conjugating method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP1817341A2 (en) * 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
WO2009006520A1 (en) * 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
SG187517A1 (en) * 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2496521C2 (en) * 2008-04-24 2013-10-27 Кантаб Байофармасьютикалз Патентс Лимитед Factor ix conjugates with extended half-life
WO2011060018A2 (en) * 2009-11-13 2011-05-19 Ikaria Development Subsidiary Two Llc Compositions and methods for using peptides, modified peptides, peptidomimetics and fibrin derivatives
UY33827A (en) * 2010-12-22 2012-07-31 Abbott Lab MEDIUM-IMMUNOGLOBULIN UNION PROTEINS AND ITS USES
JP2015510877A (en) * 2012-03-09 2015-04-13 ユーシーエル ビジネス パブリック リミテッド カンパニー Chemical modification of antibodies

Also Published As

Publication number Publication date
WO2013190292A2 (en) 2013-12-27
WO2013190292A3 (en) 2014-03-20
AU2013279099A1 (en) 2014-12-18
US20150125473A1 (en) 2015-05-07
RU2015101333A (en) 2016-08-10
ZA201408916B (en) 2015-11-25
CN104379178A (en) 2015-02-25
CA2876365A1 (en) 2013-12-27
JP2015521615A (en) 2015-07-30
MX2014015682A (en) 2015-07-23
IL235646A0 (en) 2015-01-29
KR20150023027A (en) 2015-03-04
IN2014DN10428A (en) 2015-08-21
BR112014031613A2 (en) 2017-07-25
EP2861261A2 (en) 2015-04-22
HK1204924A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
SG11201407600UA (en) Novel process for preparation of antibody conjugates and novel antibody conjugates
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407596TA (en) Conjugation reagents
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201408094YA (en) Neprilysin inhibitors
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201803676PA (en) Site specific her2 antibody drug conjugates
SG11201909011PA (en) Niraparib compositions
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201407402TA (en) Carbazole-containing sulfonamides as cryptochrome modulators
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201809594WA (en) Nicotine particles and compositions
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201903230QA (en) TCRa HOMING ENDONUCLEASE VARIANTS
SG11201805001UA (en) Method of treating influenza a
SG11201408330XA (en) Compositions and methods related to prevention and treatment of rabies infection
SG11201407337QA (en) Cyclodextrin complexation methods for formulating peptide proteasome inhibitors